May, 2015 from the Master Purchase Agreement announcement:
There is your answer: “We initially envisioned NovaGlass as a solution that will leverage our PACS and RIS solutions to give users access to full imaging features from additional endpoints. However, over the last 12 months, it has evolved to significantly more,” said Tim Law, President, Novarad. “Today, having worked closely with the team at Sphere 3D and spent time canvassing our customers, we see NovaGlass as a platform that enhances clinical workflow and can increase our ability to positively impact patient outcomes.”
Which is also why you see the current docs and specifications, that you seemingly are afraid to look at. It is called evolving...but its fine, keep your eyes firmly closed, please...